The response to second-line induction with bortezomib and dexamethasone is predictive of long-term outcomes prior to high-dose chemotherapy with autologous stem cell transplantation for multiple myeloma.
Kobayashi T, Kuroda J, Fuchida S, Murakami S, Hatsuse M, Okano A, Iwai T, Tsutsumi Y, Kamitsuji Y, Akaogi T, Kawata-Iida E, Shimizu D, Uchiyama H, Matsumoto Y, Horiike S, Nakao M, Takahashi R, Kaneko H, Uoshima N, Kobayashi Y, Shimazaki C, Taniwaki M.
Kobayashi T, et al. Among authors: tsutsumi y.
Intern Med. 2013;52(9):961-8. doi: 10.2169/internalmedicine.52.9385. Epub 2012 Mar 1.
Intern Med. 2013.
PMID: 23648714
Free article.